Abstract | BACKGROUND: We have previously reported that recombinant human plasminogen-related protein B (rPRP-B), a putative 9-kDa protein that closely resembles the activation peptide of plasminogen, has shown significant inhibition of tumor growth through inhibition of angiogenesis. Based on recent reports suggesting a close relationship between rheumatoid arthritis (RA) and angiogenesis, we hypothesized that this compound would regulate inflammatory conditions in RA. The present study therefore tested the effects of rPRP-B in the treatment of collagen-induced arthritis (CIA) to elucidate the mechanisms underlying these effects. METHODS: DBA/1J mice immunized with type II collagen to induce CIA were monitored to assess the effects of rPRP-B on clinical severity of the disease. Pathological changes in joints, including vessel formation and vascular endothelial growth factor ( VEGF) production, were examined histologically. Bone destruction was radiologically evaluated. In vitro studies on the effects of rPRP-B on cell proliferation and production of VEGF in interleukin (IL)-1β or basic fibroblast growth factor (bFGF)-stimulated human synoviocytes were also performed. RESULTS: Development of CIA was effectively inhibited by rPRP-B. Radiological examinations revealed that the protein reduced bone destruction in CIA. CIA-induced vessel formation and VEGF expression in vivo were also reduced. In vitro mechanistic studies demonstrated that rPRP-B affected human synoviocyte proliferation and VEGF production stimulated by IL-1β and bFGF. CONCLUSIONS: Given the ability to effectively promote multistep anti-angiogenic activities, including cell growth inhibition and cytokine regulation, rPRP-B represents a promising candidate for a novel therapeutic agent against RA.
|
Authors | Koichiro Tanaka, Takeshi Morii, Lawrence Weissbach, Keisuke Horiuchi, Katsuhito Takeuchi, Yoshiaki Toyama, Hideo Morioka |
Journal | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
(J Orthop Sci)
Vol. 16
Issue 4
Pg. 443-50
(Jul 2011)
ISSN: 1436-2023 [Electronic] Japan |
PMID | 21584744
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- PLGLB1 protein, human
- Recombinant Proteins
- Plasminogen
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Arthritis, Experimental
(drug therapy)
- Male
- Mice
- Mice, Inbred DBA
- Plasminogen
(therapeutic use)
- Recombinant Proteins
(therapeutic use)
|